{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:29:06Z","timestamp":1773235746492,"version":"3.50.1"},"reference-count":80,"publisher":"Endocrinology Research Centre","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Pituitary adenomas (PA) are the most common lesions of hypothalamic-pituitary region. Clinical presentations of PA depend on both hormonal activity and tumor growth characteristics. Despite the fact that PA are mostly benign, they can grow invasively and mechanically affect adjacent structures. With invasive growth of PA, radical removal is difficult and associated with a higher risk of surgical complications. Pathogenesis of PA invasiveness is not fully understood. Tumor cell invasion depends on both intercellular interactions within the tumor and interaction with extracellular matrix components (ECM). Major factors that play an important role in these processes include matrix metalloproteinase (MMP) family and tissue inhibitors of matrix metalloproteinases (TIMPs). Two MMPs were mostly studied in PA \u2013 types 2 and 9. These molecules are of interest, as they participate in degradation of type IV collagen, which is a key component of the ECM in hypothalamic-pituitary region. This review discusses the general concept of PA invasiveness, the characteristics of MMPs, and research of the relationship between these molecules and PA invasiveness.<\/jats:p>","DOI":"10.14341\/probl13631","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:22:48Z","timestamp":1773163368000},"page":"56-68","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["Matrix metalloproteinases in pituitary adenoma invasiveness"],"prefix":"10.14341","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-9487","authenticated-orcid":true,"given":"D. V.","family":"Kutakova","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-7831","authenticated-orcid":true,"given":"A. S.","family":"Lutsenko","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-2447","authenticated-orcid":true,"given":"E. G.","family":"Przhiyalkovskaya","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9718-6099","authenticated-orcid":true,"given":"V. N.","family":"Azizyan","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Landman RE, Horwith M, Peterson RE, Khandji AG, Wardlaw SL. Long-Term Survival with ACTH-Secreting Carcinoma of the Pituitary: A Case Report and Review of the Literature. J Clin Endocrinol Metab. 2002;87(7):3084-3089. doi: https:\/\/doi.org\/10.1210\/jcem.87.7.8667","DOI":"10.1210\/jcem.87.7.8667"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228-243. doi: https:\/\/doi.org\/10.1007\/s12022-017-9498-z","DOI":"10.1007\/s12022-017-9498-z"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive Pituitary Tumors. Neuroendocrinology. 2015;101(2):87-104. doi: https:\/\/doi.org\/10.1159\/000371806","DOI":"10.1159\/000371806"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mooney MA, Simon ED, Little AS. Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms. Front Surg. 2016;3. doi: https:\/\/doi.org\/10.3389\/fsurg.2016.00045","DOI":"10.3389\/fsurg.2016.00045"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Liu H-Y, Gu W-J, Wang C-Z, Ji X-J, Mu Y-M. Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas. Medicine. 2016;95(24):e3904. doi: https:\/\/doi.org\/10.1097\/MD.0000000000003904","DOI":"10.1097\/MD.0000000000003904"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Meij BP, Lopes M-BS, Ellegala DB, Alden TD, Laws ER. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002;96(2):195-208. doi: https:\/\/doi.org\/10.3171\/jns.2002.96.2.0195","DOI":"10.3171\/jns.2002.96.2.0195"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gong J, Zhao Y, Abdel-Fattah R, et al. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary. 2008;11(1):37-48. doi: https:\/\/doi.org\/10.1007\/s11102-007-0066-2","DOI":"10.1007\/s11102-007-0066-2"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1-73. doi: https:\/\/doi.org\/10.1016\/bs.pmbts.2017.02.005","DOI":"10.1016\/bs.pmbts.2017.02.005"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Serioli S, Doglietto F, Fiorindi A, et al. Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review. Cancers (Basel). 2019;11(12):1936. doi: https:\/\/doi.org\/10.3390\/cancers11121936","DOI":"10.3390\/cancers11121936"},{"key":"ref10","unstructured":"Berry RG, Caplan HJ. An overview of pituitary tumors. Ann Clin Lab Sci. 1979;9(2):94-102"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Scheithauer BW, Kovacs KT, Laws ER, Randall R V. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986;65(6):733-744. doi: https:\/\/doi.org\/10.3171\/jns.1986.65.6.0733","DOI":"10.3171\/jns.1986.65.6.0733"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hofstetter CP, Nanaszko MJ, Mubita LL, Tsiouris J, Anand VK, Schwartz TH. Volumetric classification of pituitary macroadenomas predicts outcome and morbidity following endoscopic endonasal transsphenoidal surgery. Pituitary. 2012;15(3):450-463. doi: https:\/\/doi.org\/10.1007\/s11102-011-0350-z","DOI":"10.1007\/s11102-011-0350-z"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):239-247. doi: https:\/\/doi.org\/10.1016\/j.ando.2015.04.002","DOI":"10.1016\/j.ando.2015.04.002"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Araujo-Castro M, Acitores Cancela A, Vior C, Pascual-Corrales E, Rodr\u00edguez Berrocal V. Radiological Knosp, Revised-Knosp, and Hardy\u2013Wilson Classifications for the Prediction of Surgical Outcomes in the Endoscopic Endonasal Surgery of Pituitary Adenomas: Study of 228 Cases. Front Oncol. 2022;11. doi: https:\/\/doi.org\/10.3389\/fonc.2021.807040","DOI":"10.3389\/fonc.2021.807040"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Micko ASG, W\u00f6hrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. 2015;122(4):803-811. doi: https:\/\/doi.org\/10.3171\/2014.12.JNS141083","DOI":"10.3171\/2014.12.JNS141083"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Micko A, Oberndorfer J, Weninger WJ, et al. Challenging Knosp high-grade pituitary adenomas. J Neurosurg. 2020;132(6):1739-1746. doi: https:\/\/doi.org\/10.3171\/2019.3.JNS19367","DOI":"10.3171\/2019.3.JNS19367"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Frank G, Pasquini E. Endoscopic Endonasal Cavernous Sinus Surgery, with Special Reference to Pituitary Adenomas. In: Pituitary Surgery - A Modern Approach. KARGER; 2006:64-82. doi: https:\/\/doi.org\/10.1159\/000091573","DOI":"10.1159\/000091573"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Hwang J, Seol HJ, Nam D-H, Lee J-I, Lee MH, Kong D-S. Therapeutic Strategy for Cavernous Sinus-Invading NonFunctioning Pituitary Adenomas Based on the Modified Knosp Grading System. Brain Tumor Res Treat. 2016;4(2):63. doi: https:\/\/doi.org\/10.14791\/btrt.2016.4.2.63","DOI":"10.14791\/btrt.2016.4.2.63"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ceylan S, Anik I, Koc K. A new endoscopic surgical classification and invasion criteria for pituitary adenomas involving the cavernous sinus. Turk Neurosurg. Published online 2011. doi: https:\/\/doi.org\/10.5137\/1019-5149.JTN.4149-11.0","DOI":"10.5137\/1019-5149.JTN.4149-11.0"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Knosp E, Steiner E, Kitz K, Matula C. Pituitary Adenomas with Invasion of the Cavernous Sinus Space. Neurosurgery. 1993;33(4):610-618. doi: https:\/\/doi.org\/10.1227\/00006123-199310000-00008","DOI":"10.1097\/00006123-199310000-00008"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Fernandez-Miranda JC, Zwagerman NT, Abhinav K, et al. Cavernous sinus compartments from the endoscopic endonasal approach: anatomical considerations and surgical relevance to adenoma surgery. J Neurosurg. 2018;129(2):430-441. doi: https:\/\/doi.org\/10.3171\/2017.2.JNS162214","DOI":"10.3171\/2017.2.JNS162214"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Trevisi G, Vigo V, Morena MG, et al. Comparison of Endoscopic Versus Microsurgical Resection of Pituitary Adenomas with Parasellar Extension and Evaluation of the Predictive Value of a Simple 4-Quadrant Radiologic Classification. World Neurosurg. 2019;121:e769-e774. doi: https:\/\/doi.org\/10.1016\/j.wneu.2018.09.215","DOI":"10.1016\/j.wneu.2018.09.215"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Cottier J-P, Destrieux C, Brunereau L, et al. Cavernous Sinus Invasion by Pituitary Adenoma: MR Imaging. Radiology. 2000;215(2):463-469. doi: https:\/\/doi.org\/10.1148\/radiology.215.2.r00ap18463","DOI":"10.1148\/radiology.215.2.r00ap18463"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Moreau L, Cottier J, Destrieux C, et al. Mri diagnosis of invasion of the cavernous sinus by pituitary adenomas (In french). Clin Imaging. 1998;22(5):377. doi: https:\/\/doi.org\/10.1016\/S0899-7071(98)00041-2","DOI":"10.1016\/S0899-7071(98)00041-2"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Pletnev R V., Cherebillo VYu, Shatilova AS, Bayramova SA. Intraoperative characteristics of somatotropinomas. Russian journal of neurosurgery. 2023;25(1):36-46. doi: https:\/\/doi.org\/10.17650\/1683-3295-2023-25-1-36-46","DOI":"10.17650\/1683-3295-2023-25-1-36-46"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Doglietto F, Prevedello DM, Jane JA, Han J, Laws ER. A brief history of endoscopic transsphenoidal surgery\u2014from Philipp Bozzini to the First World Congress of Endoscopic Skull Base Surgery. Neurosurg Focus. 2005;19(6):1-6. doi: https:\/\/doi.org\/10.3171\/foc.2005.19.6.4","DOI":"10.3171\/foc.2005.19.6.4"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Raithatha R, McCoul ED, Woodworth GF, Schwartz TH, Anand VK. Endoscopic endonasal approaches to the cavernous sinus. Int Forum Allergy Rhinol. 2012;2(1):9-15. doi: https:\/\/doi.org\/10.1002\/alr.20097","DOI":"10.1002\/alr.20097"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Cohen-Cohen S, Gardner PA, Alves-Belo JT, et al. The medial wall of the cavernous sinus. Part 2: Selective medial wall resection in 50 pituitary adenoma patients. J Neurosurg. 2019;131(1):131-140. doi: https:\/\/doi.org\/10.3171\/2018.5.JNS18595","DOI":"10.3171\/2018.5.JNS18595"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Truong HQ, Lieber S, Najera E, Alves-Belo JT, Gardner PA, Fernandez-Miranda JC. The medial wall of the cavernous sinus. Part 1: Surgical anatomy, ligaments, and surgical technique for its mobilization and\/or resection. J Neurosurg. 2019;131(1):122-130. doi: https:\/\/doi.org\/10.3171\/2018.3.JNS18596","DOI":"10.3171\/2018.3.JNS18596"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Nagata Y, Takeuchi K, Yamamoto T, et al. Removal of the Medial Wall of the Cavernous Sinus for Functional Pituitary Adenomas: A Technical Report and Pathologic Significance. World Neurosurg. 2019;126:53-58. doi: https:\/\/doi.org\/10.1016\/j.wneu.2019.02.134","DOI":"10.1016\/j.wneu.2019.02.134"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nishioka H, Fukuhara N, Horiguchi K, Yamada S. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes. J Neurosurg. 2014;121(3):505-510. doi: https:\/\/doi.org\/10.3171\/2014.3.JNS132214","DOI":"10.3171\/2014.3.JNS132214"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Serioli S, Doglietto F, Fiorindi A, et al. Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review. Cancers (Basel). 2019;11(12):1936. doi: https:\/\/doi.org\/10.3390\/cancers11121936","DOI":"10.3390\/cancers11121936"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Scheithauer BW, Kovacs KT, Laws ER, Randall R V. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986;65(6):733-744. doi: https:\/\/doi.org\/10.3171\/jns.1986.65.6.0733","DOI":"10.3171\/jns.1986.65.6.0733"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Selman WR, Laws ER, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg. 1986;64(3):402-407. doi: https:\/\/doi.org\/10.3171\/jns.1986.64.3.0402","DOI":"10.3171\/jns.1986.64.3.0402"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Daita G, Yonemasu Y. Dural Invasion and Proliferative Potential of Pituitary Adenomas. Neurol Med Chir (Tokyo). 1996;36(4):211-214. doi: https:\/\/doi.org\/10.2176\/nmc.36.211","DOI":"10.2176\/nmc.36.211"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas. J Neurosurg. 1987;67(6):803-806. doi: https:\/\/doi.org\/10.3171\/jns.1987.67.6.0803","DOI":"10.3171\/jns.1987.67.6.0803"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Lonser RR, Ksendzovsky A, Wind JJ, Vortmeyer AO, Oldfield EH. Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg. 2012;116(2):272-279. doi: https:\/\/doi.org\/10.3171\/2011.8.JNS11456","DOI":"10.3171\/2011.8.JNS11456"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Meij BP, Lopes M-BS, Ellegala DB, Alden TD, Laws ER. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002;96(2):195-208. doi: https:\/\/doi.org\/10.3171\/jns.2002.96.2.0195","DOI":"10.3171\/jns.2002.96.2.0195"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Villa C, Baussart B, Assi\u00e9 G, Raverot G, Roncaroli F. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocr Relat Cancer. 2023;30(8). doi: https:\/\/doi.org\/10.1530\/ERC-23-0021","DOI":"10.1530\/ERC-23-0021"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Papadimitriou E, Chatzellis E, Dimitriadi A, Kaltsas GA, Theocharis S, Alexandraki KI. Prognostic Biomarkers in Pituitary Tumours: A Systematic Review. touchREVIEWS in Endocrinology. 2023;19(2):12. doi: https:\/\/doi.org\/10.17925\/EE.2023.19.2.12","DOI":"10.17925\/EE.2023.19.2.12"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews. 2006;25(1):9-34. doi: https:\/\/doi.org\/10.1007\/s10555-006-7886-9","DOI":"10.1007\/s10555-006-7886-9"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Laronha H, Caldeira J. Structure and Function of Human Matrix Metalloproteinases. Cells. 2020;9(5):1076. doi: https:\/\/doi.org\/10.3390\/cells9051076","DOI":"10.3390\/cells9051076"},{"key":"ref43","unstructured":"Yarmolinskaya MI, Molotkov AS, Denisova VM. Matrix metalloproteinases and inhibitors: classification, mechanism of action. Journal of Obstetrics and Women\u2019s Diseases. 2012;61(1):11 (In Russ.)"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Markelova E.V. Matrix metalloproteinases: their relationship with the cytokine system, diagnostic and prognostic potential. \/\/ Immunology, allergology, infectology. 2016;(2):11-22.","DOI":"10.14427\/jipai.2016.2.11"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Zitka O, Kukacka J, Krizkov S, et al. Matrix Metalloproteinases. Curr Med Chem. 2010;17(31):3751-3768. doi: https:\/\/doi.org\/10.2174\/092986710793213724","DOI":"10.2174\/092986710793213724"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Eisen AZ, Jeffrey JJ, Gross J. Human skin collagenase, isolation and mechanism of attack on the collagen molecule. Biochimica et Biophysica Acta (BBA) - Enzymology. 1968;151(3):637-645. doi: https:\/\/doi.org\/10.1016\/0005-2744(68)90010-7","DOI":"10.1016\/0005-2744(68)90010-7"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"FREDERICK WOESSNER J. The Family of Matrix Metalloproteinases a. Ann N Y Acad Sci. 1994;732(1):11-21. doi: https:\/\/doi.org\/10.1111\/j.1749-6632.1994.tb24720.x","DOI":"10.1111\/j.1749-6632.1994.tb24720.x"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-174. doi: https:\/\/doi.org\/10.1038\/nrc745","DOI":"10.1038\/nrc745"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-674. doi: https:\/\/doi.org\/10.1038\/386671a0","DOI":"10.1038\/386671a0"},{"key":"ref50","unstructured":"Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58(5):1048-1051"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Peker S, Kurtkaya-Yap\u0131c\u0131er O, K\u0131l\u0131\u00e7 T, Pamir MN. Microsurgical anatomy of the lateral walls of the pituitary fossa. Acta Neurochir (Wien). 2005;147(6):641-649. doi: https:\/\/doi.org\/10.1007\/s00701-005-0513-7","DOI":"10.1007\/s00701-005-0513-7"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T. Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien). 1996;138(4):390-395. doi: https:\/\/doi.org\/10.1007\/BF01420300","DOI":"10.1007\/BF01420300"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Ceylan S, Anik I, Koc K, et al. Microsurgical anatomy of membranous layers of the pituitary gland and the expression of extracellular matrix collagenous proteins. Acta Neurochir (Wien). 2011;153(12):2435-2443. doi: https:\/\/doi.org\/10.1007\/s00701-011-1182-3","DOI":"10.1007\/s00701-011-1182-3"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K. Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir (Wien). 1996;138(12):1442-1448. doi: https:\/\/doi.org\/10.1007\/BF01411124","DOI":"10.1007\/BF01411124"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Yang C, Bao X, Wang R. Role of matrix Metalloproteinases in pituitary adenoma invasion. Chin Neurosurg J. 2018;4(1):2. doi: https:\/\/doi.org\/10.1186\/s41016-017-0109-0","DOI":"10.1186\/s41016-017-0109-0"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Turner HE, Nagy Zs, Esiri MM, Harris AL, Wass JAH. Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior. J Clin Endocrinol Metab. 2000;85(8):2931-2935. doi: https:\/\/doi.org\/10.1210\/jcem.85.8.6754","DOI":"10.1210\/jcem.85.8.6754"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Liu W, Matsumoto Y, Okada M, et al. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. The Journal of Medical Investigation. 2005;52(3-4):151-158. doi: https:\/\/doi.org\/10.2152\/jmi.52.151","DOI":"10.2152\/jmi.52.151"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Pan L, Chen Z, Liu Y, Zhao J. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol. 2005;74(1):71-76. doi: https:\/\/doi.org\/10.1007\/s11060-004-6150-9","DOI":"10.1007\/s11060-004-6150-9"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"G\u00fcltekin GD, \u00c7abuk B, Vural \u00c7, Ceylan S. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas. Journal of Clinical Neuroscience. 2015;22(8):1282-1287. doi: https:\/\/doi.org\/10.1016\/j.jocn.2015.02.021","DOI":"10.1016\/j.jocn.2015.02.021"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Hussaini IM, Trotter C, Zhao Y, et al. Matrix Metalloproteinase-9 Is Differentially Expressed in Nonfunctioning Invasive and Noninvasive Pituitary Adenomas and Increases Invasion in Human Pituitary Adenoma Cell Line. Am J Pathol. 2007;170(1):356-365. doi: https:\/\/doi.org\/10.2353\/ajpath.2007.060736","DOI":"10.2353\/ajpath.2007.060736"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Qu X, Yang W, Jiang M, et al. CD147 expression in pituitary adenomas and its significance for clinical outcome. Hum Pathol. 2010;41(8):1165-1171. doi: https:\/\/doi.org\/10.1016\/j.humpath.2009.10.023","DOI":"10.1016\/j.humpath.2009.10.023"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Zhang Y, He N, Zhou J, Chen Y. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma. Clin Imaging. 2011;35(3):165-173. doi: https:\/\/doi.org\/10.1016\/j.clinimag.2010.06.002","DOI":"10.1016\/j.clinimag.2010.06.002"},{"key":"ref63","unstructured":"Hui P, Xu X, Xu L, Hui G, Wu S, Lan Q. Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis. Int J Clin Exp Pathol. 2015;8(4):3556-3567"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Wang J, Voellger B, Benzel J, et al. Metalloproteinases ADAM12 and MMP\u201014 are associated with cavernous sinus invasion in pituitary adenomas. Int J Cancer. 2016;139(6):1327-1339. doi: https:\/\/doi.org\/10.1002\/ijc.30173","DOI":"10.1002\/ijc.30173"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Liu W, Kunishio K, Matsumoto Y, Okada M, Nagao S. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. Journal of Clinical Neuroscience. 2005;12(7):791-794. doi: https:\/\/doi.org\/10.1016\/j.jocn.2005.03.010","DOI":"10.1016\/j.jocn.2005.03.010"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, B\u00e9liveau R. Matrix Metalloproteinases and Their Inhibitors in Human Pituitary Tumors. Neurosurgery. 1999;45(6):1432-1441. doi: https:\/\/doi.org\/10.1097\/00006123-199912000-00033","DOI":"10.1097\/00006123-199912000-00033"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Sun B, Liu X, Yang Y, et al. The Clinical Utility of TIMP3 Expression in ACTH-Secreting Pituitary Tumor. Journal of Molecular Neuroscience. 2016;58(1):137-144. doi: https:\/\/doi.org\/10.1007\/s12031-015-0698-z","DOI":"10.1007\/s12031-015-0698-z"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Yoshida D, Nomura R, Teramoto A. Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK). J Neurooncol. 2008;89(2):141-150. doi: https:\/\/doi.org\/10.1007\/s11060-008-9606-5","DOI":"10.1007\/s11060-008-9606-5"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, B\u00e9liveau R. Matrix Metalloproteinases and Their Inhibitors in Human Pituitary Tumors. Neurosurgery. 1999;45(6):1432-1441. doi: https:\/\/doi.org\/10.1097\/00006123-199912000-00033","DOI":"10.1097\/00006123-199912000-00033"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Knappe UJ, Hagel C, Lisboa BW, Wilczak W, L\u00fcdecke DK, Saeger W. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol. 2003;106(5):471-478. doi: https:\/\/doi.org\/10.1007\/s00401-003-0747-5","DOI":"10.1007\/s00401-003-0747-5"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Yang Q, Li X. Molecular Network Basis of Invasive Pituitary Adenoma: A Review. Front Endocrinol (Lausanne). 2019;10. doi: https:\/\/doi.org\/10.3389\/fendo.2019.00007","DOI":"10.3389\/fendo.2019.00007"},{"key":"ref72","unstructured":"Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58(7):1395-1399."},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP9) markers of prostate cancer. Urol Res. 2005;33(1):44-50. doi: https:\/\/doi.org\/10.1007\/s00240-004-0440-8","DOI":"10.1007\/s00240-004-0440-8"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003;6(3):217-222. doi: https:\/\/doi.org\/10.1038\/sj.pcan.4500657","DOI":"10.1038\/sj.pcan.4500657"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-174. doi: https:\/\/doi.org\/10.1038\/nrc745","DOI":"10.1038\/nrc745"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Kasurinen A, Tervahartiala T, Laitinen A, et al. High serum MMP-14 predicts worse survival in gastric cancer. PLoS One. 2018;13(12):e0208800. doi: https:\/\/doi.org\/10.1371\/journal.pone.0208800","DOI":"10.1371\/journal.pone.0208800"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Guo H, Sun Z, Wei J, et al. Expressions of Matrix Metalloproteinases-9 and Tissue Inhibitor of Metalloproteinase-1 in Pituitary Adenomas and Their Relationships with Prognosis. Cancer Biother Radiopharm. 2019;34(1):1-6. doi: https:\/\/doi.org\/10.1089\/cbr.2018.2589","DOI":"10.1089\/cbr.2018.2589"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther. 2018;17(6):1147-1155. doi: https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0646","DOI":"10.1158\/1535-7163.MCT-17-0646"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Mucha SA, Mele\u0144-Mucha G, Godlewski A, Stepie\u0144 H. Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Archiv. 2007;450(3):335-341. doi: https:\/\/doi.org\/10.1007\/s00428-006-0351-x","DOI":"10.1007\/s00428-006-0351-x"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther. 2018;17(6):1147-1155. doi: https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0646","DOI":"10.1158\/1535-7163.MCT-17-0646"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13631\/10964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:23:14Z","timestamp":1773163394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,7]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13631","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}